In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 7, 1997, Pages 1512-1516

  Xuan, Dawei ^a   Nicolau, David P ^a   Tessier, Pamela R ^a   Bow, Laurine ^a   Quintiliani, Richard ^a   Nightingale, Charles H ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; ENDOTOXIN ANTIBODY; ESCHERICHIA COLI ENDOTOXIN; GAMMA VENIN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G;

ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNOTHERAPY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

EID: 0030857401     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.7.1512     Document Type: Article

References (29)

1. Anderson, B. M., and O. Solberg. 1984. Effect of benzylpencillin in mice infected with endotoxin-liberating or non-liberating variant strains of Neisseria meningitidis. Scand. J. Infect. Dis. 16:257-266.
2. Arditi, M., W. Kabat, and R. Yogev. 1993. Antibiotic-induced bacterial killing stimulates tumor necrosis factor-α release in whole blood. J. Infect. Dis. 167:240-244.
3. Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunol. Today 15:74-89.
4. Behre, G., I. Schedel, B. Nentwig, B. Wörmann, M. Essink, and W. Hiddemann. 1992. Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob. Agents Chemother. 36: 2139-2146.
5. Bone, R. C. 1990. The pathogenesis of sepsis. Ann. Intern. Med. 47(Suppl. 3):96.
6. Bucklin, S. E., and D. C. Morrison. 1993. Contribution of antibiotic-derived endotoxin to lethality in experimental bacteremia and sepsis, abstr. 1419, p. 379. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. DeMonty, J., and J. De Graeve. 1982. Release of endotoxic lipopolysaccharide by sensitive strain of E. coli submitted to the bactericidal action of human serum. Med. Microbiol. Immunol. 170:265-277.
8. Durum, S. K., and J. J. Oppenheim. 1993. Proinflammatory cytokines and immunity, p. 801-815. In W. E. Paul (ed.), Fundamental immunology, 3rd ed. Raven Press, Ltd., New York, N.Y.
9. Elin, R. J., A. L. Sandberg, and D. L. Rosenstreich. 1976. Comparison of the pyrogenicity, limulus activity, mitogenicity and complement reactivity of several bacterial endotoxins and related compounds. J. Immunol. 117:1238-1242.
10. Eng, R. H. K., et al. 1993. Effect of antibiotics on endotoxin release from gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 16:185-189.
11. Evans, M. E., and M. Pollack. 1993. Effect of antibiotic class and concentration on the release of lipopolysaccharide from E. coli. J. Infect. Dis. 167:1336-1343.
12. Freudenberg, M. A., D. Keppler, and C. Galanos. 1986. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect. Immun. 51:891-895.
13. Greenman, R. L., R. M. H. Schein, M. A. Martin, et al. 1991. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1102.
14. Hopkin, B. D. A. 1977. Too-rapid destruction of gram-negative organisms. Lancet ii:603-604.
15. Hopkin, B. D. A. 1978. Frapper fort ou frapper documnet: a gram-negative dillemma. Lancet 11:1193-1194.
16. Hopkin, B. D. A. 1985. A nasty shock from antibiotics. Lancet ii:594.
17. Jorgensen, J. H. 1986. Clinical applications of the limulus amebocyte lysate test, p. 127-160. In R. A. Proctor (ed.), Clinical aspects of endotoxin shock. Handbook of endotoxin. vol. 4. Elsevier, Amsterdam. The Netherlands.
18. Leeson, M., Y. Fujihara, and D. C. Morrison. 1993. Induction of human monocyte proinflammatory response by LPS and LPS-containing bacterial constituents, abstr. 18. p. 122. In Program and abstracts of the 33rd Interscience Conference tin Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. Mattsby-Baltzer, I., K. Lindgren, B. Lindholm, and L. Edebo. 1991. Endotoxin shedding by enterobacteria: free and cell-bound endotoxin differ in Limulus activity. Infect. Immun. 59:689-695.
20. Mustafa, M. M., et al. 1989. Increased endotoxin and interleukin-1β concentrations in cerebrospinal fluids of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. J. Infect. Dis. 160:891-895.
21. Neu, I. 1980. Der therapeutische wert von Immunoglobulinen bei Indektionen des Zentralnerversystems. Med. Klin. 75:554-557.
22. Sahm, D. F., and J. A. Washington. 1991. Antibacterial susceptibility tests: dilution methods, p. 1105-1115. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
23. Schade, G. 1975. Einsatz von Gamma-Venin bei bronchopneumonien. Gelben Hefte XV 2:79.
24. Sedlacek, H. H. 1984. Unsepezitische und spezifische Immunabwehr. Biomedicine 5:16-21.
25. Shenep, J. L., R. P. Barton, and K. A. Mogan. 1985. Role of antibiotic class in the rate of liberation of endotoxin during the therapy for experimental gram-negative bacterial sepsis. J. Infect. Dis. 151:1012-1018.
26. Tomasulo, P. A., J. Levin, P. A. Murphy, and J. A. Winkelstein. 1977. Biological activities of tritiated endotoxins: correlation of the Limulus lysate assay with rabbit pyrogen and complement-activation assays for endotoxin. J. Lab. Clin. Med. 89:308-315.
27. Van den Berg, C., et al. 1992. Delayed antibiotic-induced lysis of E. coli in vitro K correlated with enhancement of LPS release. Scand. J. Infect. Dis. 24:619-627.
28. Warren, H. S., R. L. Danner, and R. S. Munford. 1992. Anti-endotoxin monoclonal antibodies. N. Engl. J. Med. 326:1153-1157.
29. Ziegler, E. J., C. J. Fisher, Jr., C. L. Sprung, et al. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324:429-436.